Treatment of alopecia areata with oral tacrolimus

Treatment of alopecia areata with oral tacrolimus - Treatment of alopecia areata with oral tacrolimus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051180073

Enrollment

Registered

2019-02-25

Start date

2019-02-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia areata

Interventions

Acute cases: Methylprednisolone half pulse (500 mg/d, 3 days) followed by 12 week treatment of oral tacrolimus. Trough serum levels of tacrolimus are controlled at 5-10ng/mL Chronic cases: 12 week

D016559

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Confirmation of the diagnosis Acute cases: 25% or more hair loss in 3 months or less for the first time Chronic cases: 25% or more hair loss for 6 months or more; uncontrolled by existing treatments

Exclusion criteria

Exclusion criteria: Heart, kidney, or endocrine disorders Infectious diseases: viral hepatitis, tuberculosis, syphilis, pneumonia, urinary tract infections Mental diseases Current or past cancers Current or possible pregnancy Others considered by doctors Contraindication of oral tacrolimus

Design outcomes

Primary

Measure	Time frame
Hair regrowth after 12 week treatment of oral tacrolimus	—

Contacts

Public ContactTeruki Dainichi

Kyoto University

dainichi@kuhp.kyoto-u.ac.jp+81-75-751-3310

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026